PTC Therapeutics (NASDAQ:PTCT) will collaborate with non-profit Odylia Therapeutics to develop novel gene therapies based on a synthetic vector called Anc80 that was developed at Massachusetts Eye and Ear.
The lead program will be RP-GRIP1, the defective protein in a rare childhood retinal dystrophy called Leber Congenital Amaurosis 6 (LCA6).
Financial terms are not disclosed.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.